ST. JOSEPH, Mich., Feb. 20 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Johnson & Johnson Pharmaceutical Research & Development, (J&JPRD), a division of Janssen Pharmaceutica N.V., has extended their MetaCore(TM) license to now include MetaBase(TM), a database J&JPRD will primarily use for biomarker discovery.
“We are pleased to have this relationship extended,” said Julie Bryant, Vice President of Business Development at GeneGo. “We look forward to enhancing our collaboration with the MetaBase integration.”
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 2.5, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company’s web site at www.genego.com.
MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.
GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
